Genflow Biosciences Provides Half Year Corporate Update on SIRT6 Programs, IP Progress and Strategic Partnerships LONDON, UK / ACCESS Newswire / June 17, 2025 / Genflow Biosciences Plc ...

ROCKVILLE, MD / ACCESS Newswire / June 16, 2025 /uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to ...

The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...

How can early decisions in cell and gene therapy clinical development impact downstream progress toward commercialization and ...

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients ...

GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...

Brain Tumours, particularly malignant types such as glioblastoma multiforme (GBM), continue to pose a significant clinical ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying ...

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for ...

Pompe Disease Market Insight - DelveInsightThe Pompe disease treatment market is experiencing significant expansion, driven by increasing di ...